Please Wait...

Study Points Way to Increased Efficacy in Respiratory Syncytial Virus Vaccine

Respiratory syncytial virus (RSV) is increasingly being recognized as an important cause of disease in older adults worldwide. Its impact is estimated to be comparable to or even greater than that of influenza. However, RSV is not typically tested for, as there is no specific treatment. A successful vaccine would represent a vital breakthrough, deeply benefiting this growing segment of the population.

To that end, a double-blind phase 1 study was conducted with subjects 60 years of age and older. The subjects received vaccines containing escalating doses of soluble RSV fusion protein(sF) alone or adjuvanted with glucopyranosyl lipid A, a toll-like receptor-4 agonist, in 2% stable emulsion (GLA-SE). The full report of the study with its conclusions can be read in here.

One of the authors of this key study is Craig Curtis, MD, CPI, and Chief Medical Officer at Bioclinica. Dr. Curtis is a Florida-licensed physician with Board Certification in Family Medicine. He has over 15 years of clinical trial experience covering all phases of research and numerous therapeutic areas. He has served as Principal Investigator on over 200 trials in the areas of general medicine, psychiatry, neurology, analgesia, and early clinical development.

Dr. Curtis is a member of the Association of Clinical Research Professionals (ACRP), the Drug Information Association (DIA), and the American Society for Clinical Pharmacology and Therapeutics (ASCPT). He earned his medical degree from Northeastern Ohio University College of Medicine.

Read the study now:
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-likereceptor-4 agonist and stable emulsion adjuvant

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Come talk to Bioclinica at #ASCO19! See why we're the world leader in #oncology imaging, helping to assess efficacy… https://t.co/MyomMS0Rvt
Bioclinica (2 days ago)
Great insights for sponsors conducting #NAFLD #NASH #clinicaltrials. https://t.co/TG1WwRhVE8
Bioclinica (3 days ago)
In Beijing for DIA China next week? If so, drop by Bioclinica's exhibit or catch our talk in the Randomization & Cl… https://t.co/LCNpNHabo2
Bioclinica (4 days ago)
Greetings from Milan! Bioclinica looks forward to connecting with our #pharma and #CRO friends at #octEurope! Raggy… https://t.co/KqG99HqDWA
Bioclinica (5 days ago)
Could EDC software be a game changer in your clinical trial? Here's what to look for in evaluating different syste… https://t.co/MyxooYMwqk
Bioclinica (5 days ago)
This week at OCT Europe, #pharma #CRO companies can get a look at Bioclinica's award-winning clinical adjudication… https://t.co/jzEexOMDZA
Bioclinica (6 days ago)

Latest Blogs:

Medical Imaging of Non-Alcoholic Fatty Liver Diseases in Clinical Trials
EDC Provider Selection
Site Payments Solutions
Nonalcoholic steatohepatitis (NASH) development programs
Dr. Joby John
Transformational Trends in Investigator Site Payments
Clinical Supply Chain Success: Leveraging Technology
Blood pressure monitor
Prescription box